Former Bausch + Lomb CEO Saunders to head Forest; Icahn approves
This article was originally published in Scrip
Executive Summary
After Brent Saunders saw Bausch + Lomb through a transformation that made the company attractive to recent acquirer Valeant Pharmaceuticals, industry observers wondered where the Schering-Plough veteran would work his magic next, and now they have their answer: Forest Laboratories.
You may also be interested in...
Activist Investors Seek Action At Allergan, But Are They Aligned?
Investors want to separate the CEO and chairman roles held by Brent Saunders, among other demands, but it's unclear whether new investor Carl Icahn – a prior Saunders supporter – will pursue the same causes.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.